少即是多:子宫内膜癌微创子宫切除术后常规实验室检查的临床效用
单机构回顾性队列研究纳入2014年6月至2017年6月因子宫内膜癌行微创子宫切除术的649例患者,全部患者术后均被开具实验室检查,仅4.0%因结果改变管理,其中88%已有临床状态改变会触发检查,仅0.5%无症状;常规检查增加医院成本292000美元。作者认为常规术后实验室检查不太可能带来显著管理改变,应在有临床指征时开具而非作为常规管理。
要点
- 649例子宫内膜癌微创子宫切除术后患者全部被开具实验室检查,仅4.0%因结果改变管理。
- 26例管理改变者中88%已有临床状态改变会触发检查,仅3例(0.5%)无症状。
- 常规术后实验室检查使医院成本增加292000美元。
核心结论
- 常规术后实验室检查不太可能为子宫内膜癌微创子宫切除术女性带来显著管理改变,且可能增加成本而无明显临床获益。
- 在严格术后指南背景下,实验室检查应在有临床指征时开具,而非作为子宫内膜癌微创子宫切除术后的常规管理组成部分。
研究设计与样本
- 单机构回顾性队列研究,纳入2014年6月至2017年6月由妇科肿瘤医生行微创子宫切除术的子宫内膜癌患者649例。
- 从病历中手工提取人口学、术前合并症、手术与术后数据及病理结果,并使用医院层面成本数据计算实验室检查的经济负担。
主要发现
- 649例中91.4%为白人,平均年龄61岁,平均体质指数38.0 kg/m2。
- 最常见合并症为糖尿病(31.9%,n=207)、慢性肺病(7.9%,n=51)和充血性心力衰竭(3.2%,n=21)。
- 中位手术时间151分钟(范围61-278),中位估计失血量100 mL(范围10-1500),68.6%(n=445)行淋巴结清扫。
- 全部患者均被开具术后实验室检查:100%全血细胞计数、99.7%生化、62.9%镁、46.8%磷、37.4%钙、1.2%肝功能。
- 26例(4.0%)因术后实验室结果改变管理;其中88%已有临床状态改变会触发检查,仅3例(全队列0.5%)无症状:1例因无症状贫血输血,另2例无糖尿病诊断者因高血糖接受干预。
临床怎么用
- 作者认为,在严格术后指南背景下,实验室检查应在有临床指征时开具,而非作为子宫内膜癌微创子宫切除术后的常规管理组成部分,因为常规检查不太可能带来显著管理改变且可能增加成本而无明显临床获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the increasing rates of same-day discharge following minimally invasive surgery for endometrial cancer, the need for and value of routine postoperative testing is unclear. OBJECTIVE: This study aimed to determine whether routine postoperative laboratory testing following minimally invasive hysterectomy for endometrial cancer leads to clinically significant changes in postoperative care. STUDY DESIGN: This was a single-institution retrospective cohort study of patients undergoing minimally invasive hysterectomy for endometrial cancer by a gynecologic oncologist between June 2014 and June 2017. Patient demographics, preoperative comorbidities, operative and postoperative data, and pathologic findings were manually extracted from the patients' medical records. The financial burden of laboratory testing was computed using hospital-level cost data. RESULTS: Of the 649 women included in the analysis, most (91.4%) were White, with a mean age of 61 years, and mean body mass index of 38.0 kg/m2. The most common comorbidities were diabetes mellitus (31.9%, n=207), chronic pulmonary disease (7.9%, n=51), and congestive heart failure (3.2%, n=21). Median operative time was 151 minutes (range, 61-278), and median estimated blood loss was 100 mL (range, 10-1500). Most patients (68.6%, n=445) underwent lymphadenectomy. All patients had postoperative laboratory tests ordered: 100% complete blood count, 99.7% chemistry, 62.9% magnesium, 46.8% phosphate, 37.4% calcium, and 1.2% liver function tests. Twenty-six patients (4.0%) had a change in management owing to postoperative laboratory test results. Of these 26 women, 88% experienced a change in clinical status that would have otherwise prompted testing. Only 3 (0.5% of entire cohort) were asymptomatic: 1 received a blood transfusion for asymptomatic anemia, and the other 2, who did not carry a diagnosis of diabetes mellitus, had interventions for hyperglycemia. On univariable analysis, peripheral and cerebrovascular disease, diabetes mellitus with end-organ damage, and a Charlson Comorbidity Index of ≥3 were associated with increased odds of change in management; these were not significant on multivariable analysis. Routine postoperative laboratory evaluation in this cohort increased hospital costs by $292,000. CONCLUSION: Routine postoperative laboratory tests are unlikely to lead to significant changes in management for women undergoing minimally invasive hysterectomy for endometrial cancer, and may increase cost without providing a discernible clinical benefit. In the setting of strict postoperative guidelines, laboratory tests should be ordered when clinically indicated rather than as part of routine postoperative management for women undergoing minimally invasive hysterectomy for endometrial cancer.
引用
- Lightfoot MDS, Felix AS, Calo CA, et al. Less is more: clinical utility of postoperative laboratory testing following minimally invasive hysterectomy for endometrial cancer. Am J Obstet Gynecol. 2022. PMID: 35931127. doi:10.1016/j.ajog.2022.07.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。